Clinical differences among patients with myeloperoxidase–antineutrophil cytoplasmic antibody–positive interstitial lung disease

Introduction Patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis and idiopathic interstitial lung diseases (IIPs) are positive for myeloperoxidase (MPO)–ANCA. MPO–ANCA-positive vasculitis mainly comprises microscopic polyangiitis (MPA) and unclassifiable vasculitis. These...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical rheumatology 2023-02, Vol.42 (2), p.479-488
Hauptverfasser: Yamaguchi, Koichi, Yamaguchi, Aya, Ito, Masashi, Wakamatsu, Ikuo, Itai, Miki, Muto, Sohei, Uno, Shogo, Aikawa, Masaki, Kouno, Shunichi, Takemura, Masao, Yatomi, Masakiyo, Aoki-Saito, Haruka, Koga, Yasuhiko, Hara, Kenichiro, Motegi, Shinsuke, Tsukida, Mayuko, Ota, Fumie, Tsukada, Yoshito, Motegi, Mitsuru, Nakasatomi, Masao, Sakairi, Toru, Ikeuchi, Hidekazu, Kaneko, Yoriaki, Hiromura, Keiju, Maeno, Toshitaka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 488
container_issue 2
container_start_page 479
container_title Clinical rheumatology
container_volume 42
creator Yamaguchi, Koichi
Yamaguchi, Aya
Ito, Masashi
Wakamatsu, Ikuo
Itai, Miki
Muto, Sohei
Uno, Shogo
Aikawa, Masaki
Kouno, Shunichi
Takemura, Masao
Yatomi, Masakiyo
Aoki-Saito, Haruka
Koga, Yasuhiko
Hara, Kenichiro
Motegi, Shinsuke
Tsukida, Mayuko
Ota, Fumie
Tsukada, Yoshito
Motegi, Mitsuru
Nakasatomi, Masao
Sakairi, Toru
Ikeuchi, Hidekazu
Kaneko, Yoriaki
Hiromura, Keiju
Maeno, Toshitaka
description Introduction Patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis and idiopathic interstitial lung diseases (IIPs) are positive for myeloperoxidase (MPO)–ANCA. MPO–ANCA-positive vasculitis mainly comprises microscopic polyangiitis (MPA) and unclassifiable vasculitis. These diseases are frequently complicated by interstitial lung disease (ILD). Few studies have reported the clinical differences between the subtypes of MPO–ANCA-positive ILD. Therefore, this study aimed to examine the clinical findings and courses of MPO–ANCA-positive ILD. Method This retrospective study enrolled 100 patients with MPO–ANCA-positive ILD who were categorized into three groups: MPA ( n  = 44), unclassifiable vasculitis ( n  = 29), and IIP ( n  = 27). Our study compared the clinical findings and prognosis of these patients and analyzed the poor prognostic factors. Furthermore, we assessed the association between the patients with and without acute exacerbation of ILD (AE-ILD). Results Our study found clinical differences in serum markers, clinical symptoms, and treatment regimens among the three groups. ILD complications, as the main cause of death, differed among the three groups ( P  = 0.04). Patients with unclassifiable vasculitis showed higher survival rates than those with IIP ( P  = 0.046). Patients with AE-ILD showed fewer general symptoms ( P  = 0.02) and lower survival rates ( P  
doi_str_mv 10.1007/s10067-022-06388-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2721262828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2768915257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-7849b35b31ffb60810d4189524f03f90ea74962e0e90bf4f99fbf72ff9a53c593</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS0EopeWF2CBIrFhE_BPHNvL6qqlSJXYwNpyknHryrFT24HeHRKPwBvyJHV7SyuxYOORNd-cM5qD0BuCPxCMxcdc3160mNIW90zKlj9DG9KxrlWqU8_RBguBW0aUPECvcr7CGFOpyEt0wHqiKic26NfWu-BG45vJWQsJwgi5MXMMF81iioNQcvPDlctm3oGPC6R44yaT4c_P3yYUF2AtKS6XzjfjrsTFmzy7sblrDXHaVWqJ2RX3HRoXCqRc6qe6-bUaTC5DlTpCL6zxGV4_1EP07fTk6_asPf_y6fP2-LwdmeClFbJTA-MDI9YOPZYETx2RitPOYmYVBiM61VPAoPBgO6uUHayg1irD2cgVO0Tv97pLitcr5KJnl0fw3gSIa9ZUUEJ7Kqms6Lt_0Ku4plC3q1Rfj8gpF5Wie2pMMecEVi_JzSbtNMH6LiK9j0jXiPR9RJrXobcP0usww_Q48jeTCrA9kGsrXEB68v6P7C2vraG-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2768915257</pqid></control><display><type>article</type><title>Clinical differences among patients with myeloperoxidase–antineutrophil cytoplasmic antibody–positive interstitial lung disease</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Yamaguchi, Koichi ; Yamaguchi, Aya ; Ito, Masashi ; Wakamatsu, Ikuo ; Itai, Miki ; Muto, Sohei ; Uno, Shogo ; Aikawa, Masaki ; Kouno, Shunichi ; Takemura, Masao ; Yatomi, Masakiyo ; Aoki-Saito, Haruka ; Koga, Yasuhiko ; Hara, Kenichiro ; Motegi, Shinsuke ; Tsukida, Mayuko ; Ota, Fumie ; Tsukada, Yoshito ; Motegi, Mitsuru ; Nakasatomi, Masao ; Sakairi, Toru ; Ikeuchi, Hidekazu ; Kaneko, Yoriaki ; Hiromura, Keiju ; Maeno, Toshitaka</creator><creatorcontrib>Yamaguchi, Koichi ; Yamaguchi, Aya ; Ito, Masashi ; Wakamatsu, Ikuo ; Itai, Miki ; Muto, Sohei ; Uno, Shogo ; Aikawa, Masaki ; Kouno, Shunichi ; Takemura, Masao ; Yatomi, Masakiyo ; Aoki-Saito, Haruka ; Koga, Yasuhiko ; Hara, Kenichiro ; Motegi, Shinsuke ; Tsukida, Mayuko ; Ota, Fumie ; Tsukada, Yoshito ; Motegi, Mitsuru ; Nakasatomi, Masao ; Sakairi, Toru ; Ikeuchi, Hidekazu ; Kaneko, Yoriaki ; Hiromura, Keiju ; Maeno, Toshitaka</creatorcontrib><description>Introduction Patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis and idiopathic interstitial lung diseases (IIPs) are positive for myeloperoxidase (MPO)–ANCA. MPO–ANCA-positive vasculitis mainly comprises microscopic polyangiitis (MPA) and unclassifiable vasculitis. These diseases are frequently complicated by interstitial lung disease (ILD). Few studies have reported the clinical differences between the subtypes of MPO–ANCA-positive ILD. Therefore, this study aimed to examine the clinical findings and courses of MPO–ANCA-positive ILD. Method This retrospective study enrolled 100 patients with MPO–ANCA-positive ILD who were categorized into three groups: MPA ( n  = 44), unclassifiable vasculitis ( n  = 29), and IIP ( n  = 27). Our study compared the clinical findings and prognosis of these patients and analyzed the poor prognostic factors. Furthermore, we assessed the association between the patients with and without acute exacerbation of ILD (AE-ILD). Results Our study found clinical differences in serum markers, clinical symptoms, and treatment regimens among the three groups. ILD complications, as the main cause of death, differed among the three groups ( P  = 0.04). Patients with unclassifiable vasculitis showed higher survival rates than those with IIP ( P  = 0.046). Patients with AE-ILD showed fewer general symptoms ( P  = 0.02) and lower survival rates ( P  &lt; 0.01) than those without AE-ILD. In multivariate analysis, AE-ILD development was a strong poor prognostic factor for MPO–ANCA-positive ILD. Conclusions The subtypes of MPO–ANCA-positive ILD have different clinical features and prognoses. Patients who develop AE-ILD require careful evaluation of clinical courses. Key Points • In myeloperoxidase (MPO)–antineutrophil cytoplasmic antibody (ANCA)–positive interstitial lung disease (ILD), patients with unclassifiable vasculitis showed a better prognosis than those with idiopathic ILD. . • Development of acute exacerbation in ILD was a strong poor prognostic factor in patients with MPO–ANCA-positive ILD. .</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-022-06388-5</identifier><identifier>PMID: 36194347</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications ; Antibodies ; Antibodies, Antineutrophil Cytoplasmic ; Antineutrophil cytoplasmic antibodies ; Humans ; Lung diseases ; Lung Diseases, Interstitial ; Medical prognosis ; Medical treatment ; Medicine ; Medicine &amp; Public Health ; Microscopic Polyangiitis - complications ; Multivariate analysis ; Original Article ; Patients ; Peroxidase ; Prognosis ; Retrospective Studies ; Rheumatology ; Survival ; Vasculitis</subject><ispartof>Clinical rheumatology, 2023-02, Vol.42 (2), p.479-488</ispartof><rights>The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-7849b35b31ffb60810d4189524f03f90ea74962e0e90bf4f99fbf72ff9a53c593</citedby><cites>FETCH-LOGICAL-c375t-7849b35b31ffb60810d4189524f03f90ea74962e0e90bf4f99fbf72ff9a53c593</cites><orcidid>0000-0003-0085-7728 ; 0000-0001-6840-515X ; 0000-0002-3982-7561 ; 0000-0002-8612-8915 ; 0000-0002-8428-2046 ; 0000-0002-4974-9026 ; 0000-0001-8019-7912 ; 0000-0003-0701-6753 ; 0000-0002-8753-7067 ; 0000-0002-0768-7090 ; 0000-0003-4567-6082 ; 0000-0002-8428-1617 ; 0000-0002-4303-330X ; 0000-0003-1198-8520 ; 0000-0002-7047-7870 ; 0000-0002-9490-8364 ; 0000-0001-9329-1203 ; 0000-0001-9030-2050 ; 0000-0003-4212-7352 ; 0000-0002-9498-6995 ; 0000-0001-5755-0781 ; 0000-0003-1154-1454 ; 0000-0002-6251-7414 ; 0000-0003-2804-485X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-022-06388-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-022-06388-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36194347$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamaguchi, Koichi</creatorcontrib><creatorcontrib>Yamaguchi, Aya</creatorcontrib><creatorcontrib>Ito, Masashi</creatorcontrib><creatorcontrib>Wakamatsu, Ikuo</creatorcontrib><creatorcontrib>Itai, Miki</creatorcontrib><creatorcontrib>Muto, Sohei</creatorcontrib><creatorcontrib>Uno, Shogo</creatorcontrib><creatorcontrib>Aikawa, Masaki</creatorcontrib><creatorcontrib>Kouno, Shunichi</creatorcontrib><creatorcontrib>Takemura, Masao</creatorcontrib><creatorcontrib>Yatomi, Masakiyo</creatorcontrib><creatorcontrib>Aoki-Saito, Haruka</creatorcontrib><creatorcontrib>Koga, Yasuhiko</creatorcontrib><creatorcontrib>Hara, Kenichiro</creatorcontrib><creatorcontrib>Motegi, Shinsuke</creatorcontrib><creatorcontrib>Tsukida, Mayuko</creatorcontrib><creatorcontrib>Ota, Fumie</creatorcontrib><creatorcontrib>Tsukada, Yoshito</creatorcontrib><creatorcontrib>Motegi, Mitsuru</creatorcontrib><creatorcontrib>Nakasatomi, Masao</creatorcontrib><creatorcontrib>Sakairi, Toru</creatorcontrib><creatorcontrib>Ikeuchi, Hidekazu</creatorcontrib><creatorcontrib>Kaneko, Yoriaki</creatorcontrib><creatorcontrib>Hiromura, Keiju</creatorcontrib><creatorcontrib>Maeno, Toshitaka</creatorcontrib><title>Clinical differences among patients with myeloperoxidase–antineutrophil cytoplasmic antibody–positive interstitial lung disease</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>Introduction Patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis and idiopathic interstitial lung diseases (IIPs) are positive for myeloperoxidase (MPO)–ANCA. MPO–ANCA-positive vasculitis mainly comprises microscopic polyangiitis (MPA) and unclassifiable vasculitis. These diseases are frequently complicated by interstitial lung disease (ILD). Few studies have reported the clinical differences between the subtypes of MPO–ANCA-positive ILD. Therefore, this study aimed to examine the clinical findings and courses of MPO–ANCA-positive ILD. Method This retrospective study enrolled 100 patients with MPO–ANCA-positive ILD who were categorized into three groups: MPA ( n  = 44), unclassifiable vasculitis ( n  = 29), and IIP ( n  = 27). Our study compared the clinical findings and prognosis of these patients and analyzed the poor prognostic factors. Furthermore, we assessed the association between the patients with and without acute exacerbation of ILD (AE-ILD). Results Our study found clinical differences in serum markers, clinical symptoms, and treatment regimens among the three groups. ILD complications, as the main cause of death, differed among the three groups ( P  = 0.04). Patients with unclassifiable vasculitis showed higher survival rates than those with IIP ( P  = 0.046). Patients with AE-ILD showed fewer general symptoms ( P  = 0.02) and lower survival rates ( P  &lt; 0.01) than those without AE-ILD. In multivariate analysis, AE-ILD development was a strong poor prognostic factor for MPO–ANCA-positive ILD. Conclusions The subtypes of MPO–ANCA-positive ILD have different clinical features and prognoses. Patients who develop AE-ILD require careful evaluation of clinical courses. Key Points • In myeloperoxidase (MPO)–antineutrophil cytoplasmic antibody (ANCA)–positive interstitial lung disease (ILD), patients with unclassifiable vasculitis showed a better prognosis than those with idiopathic ILD. . • Development of acute exacerbation in ILD was a strong poor prognostic factor in patients with MPO–ANCA-positive ILD. .</description><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications</subject><subject>Antibodies</subject><subject>Antibodies, Antineutrophil Cytoplasmic</subject><subject>Antineutrophil cytoplasmic antibodies</subject><subject>Humans</subject><subject>Lung diseases</subject><subject>Lung Diseases, Interstitial</subject><subject>Medical prognosis</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Microscopic Polyangiitis - complications</subject><subject>Multivariate analysis</subject><subject>Original Article</subject><subject>Patients</subject><subject>Peroxidase</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Survival</subject><subject>Vasculitis</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1u1TAQhS0EopeWF2CBIrFhE_BPHNvL6qqlSJXYwNpyknHryrFT24HeHRKPwBvyJHV7SyuxYOORNd-cM5qD0BuCPxCMxcdc3160mNIW90zKlj9DG9KxrlWqU8_RBguBW0aUPECvcr7CGFOpyEt0wHqiKic26NfWu-BG45vJWQsJwgi5MXMMF81iioNQcvPDlctm3oGPC6R44yaT4c_P3yYUF2AtKS6XzjfjrsTFmzy7sblrDXHaVWqJ2RX3HRoXCqRc6qe6-bUaTC5DlTpCL6zxGV4_1EP07fTk6_asPf_y6fP2-LwdmeClFbJTA-MDI9YOPZYETx2RitPOYmYVBiM61VPAoPBgO6uUHayg1irD2cgVO0Tv97pLitcr5KJnl0fw3gSIa9ZUUEJ7Kqms6Lt_0Ku4plC3q1Rfj8gpF5Wie2pMMecEVi_JzSbtNMH6LiK9j0jXiPR9RJrXobcP0usww_Q48jeTCrA9kGsrXEB68v6P7C2vraG-</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Yamaguchi, Koichi</creator><creator>Yamaguchi, Aya</creator><creator>Ito, Masashi</creator><creator>Wakamatsu, Ikuo</creator><creator>Itai, Miki</creator><creator>Muto, Sohei</creator><creator>Uno, Shogo</creator><creator>Aikawa, Masaki</creator><creator>Kouno, Shunichi</creator><creator>Takemura, Masao</creator><creator>Yatomi, Masakiyo</creator><creator>Aoki-Saito, Haruka</creator><creator>Koga, Yasuhiko</creator><creator>Hara, Kenichiro</creator><creator>Motegi, Shinsuke</creator><creator>Tsukida, Mayuko</creator><creator>Ota, Fumie</creator><creator>Tsukada, Yoshito</creator><creator>Motegi, Mitsuru</creator><creator>Nakasatomi, Masao</creator><creator>Sakairi, Toru</creator><creator>Ikeuchi, Hidekazu</creator><creator>Kaneko, Yoriaki</creator><creator>Hiromura, Keiju</creator><creator>Maeno, Toshitaka</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0085-7728</orcidid><orcidid>https://orcid.org/0000-0001-6840-515X</orcidid><orcidid>https://orcid.org/0000-0002-3982-7561</orcidid><orcidid>https://orcid.org/0000-0002-8612-8915</orcidid><orcidid>https://orcid.org/0000-0002-8428-2046</orcidid><orcidid>https://orcid.org/0000-0002-4974-9026</orcidid><orcidid>https://orcid.org/0000-0001-8019-7912</orcidid><orcidid>https://orcid.org/0000-0003-0701-6753</orcidid><orcidid>https://orcid.org/0000-0002-8753-7067</orcidid><orcidid>https://orcid.org/0000-0002-0768-7090</orcidid><orcidid>https://orcid.org/0000-0003-4567-6082</orcidid><orcidid>https://orcid.org/0000-0002-8428-1617</orcidid><orcidid>https://orcid.org/0000-0002-4303-330X</orcidid><orcidid>https://orcid.org/0000-0003-1198-8520</orcidid><orcidid>https://orcid.org/0000-0002-7047-7870</orcidid><orcidid>https://orcid.org/0000-0002-9490-8364</orcidid><orcidid>https://orcid.org/0000-0001-9329-1203</orcidid><orcidid>https://orcid.org/0000-0001-9030-2050</orcidid><orcidid>https://orcid.org/0000-0003-4212-7352</orcidid><orcidid>https://orcid.org/0000-0002-9498-6995</orcidid><orcidid>https://orcid.org/0000-0001-5755-0781</orcidid><orcidid>https://orcid.org/0000-0003-1154-1454</orcidid><orcidid>https://orcid.org/0000-0002-6251-7414</orcidid><orcidid>https://orcid.org/0000-0003-2804-485X</orcidid></search><sort><creationdate>20230201</creationdate><title>Clinical differences among patients with myeloperoxidase–antineutrophil cytoplasmic antibody–positive interstitial lung disease</title><author>Yamaguchi, Koichi ; Yamaguchi, Aya ; Ito, Masashi ; Wakamatsu, Ikuo ; Itai, Miki ; Muto, Sohei ; Uno, Shogo ; Aikawa, Masaki ; Kouno, Shunichi ; Takemura, Masao ; Yatomi, Masakiyo ; Aoki-Saito, Haruka ; Koga, Yasuhiko ; Hara, Kenichiro ; Motegi, Shinsuke ; Tsukida, Mayuko ; Ota, Fumie ; Tsukada, Yoshito ; Motegi, Mitsuru ; Nakasatomi, Masao ; Sakairi, Toru ; Ikeuchi, Hidekazu ; Kaneko, Yoriaki ; Hiromura, Keiju ; Maeno, Toshitaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-7849b35b31ffb60810d4189524f03f90ea74962e0e90bf4f99fbf72ff9a53c593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications</topic><topic>Antibodies</topic><topic>Antibodies, Antineutrophil Cytoplasmic</topic><topic>Antineutrophil cytoplasmic antibodies</topic><topic>Humans</topic><topic>Lung diseases</topic><topic>Lung Diseases, Interstitial</topic><topic>Medical prognosis</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Microscopic Polyangiitis - complications</topic><topic>Multivariate analysis</topic><topic>Original Article</topic><topic>Patients</topic><topic>Peroxidase</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Survival</topic><topic>Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamaguchi, Koichi</creatorcontrib><creatorcontrib>Yamaguchi, Aya</creatorcontrib><creatorcontrib>Ito, Masashi</creatorcontrib><creatorcontrib>Wakamatsu, Ikuo</creatorcontrib><creatorcontrib>Itai, Miki</creatorcontrib><creatorcontrib>Muto, Sohei</creatorcontrib><creatorcontrib>Uno, Shogo</creatorcontrib><creatorcontrib>Aikawa, Masaki</creatorcontrib><creatorcontrib>Kouno, Shunichi</creatorcontrib><creatorcontrib>Takemura, Masao</creatorcontrib><creatorcontrib>Yatomi, Masakiyo</creatorcontrib><creatorcontrib>Aoki-Saito, Haruka</creatorcontrib><creatorcontrib>Koga, Yasuhiko</creatorcontrib><creatorcontrib>Hara, Kenichiro</creatorcontrib><creatorcontrib>Motegi, Shinsuke</creatorcontrib><creatorcontrib>Tsukida, Mayuko</creatorcontrib><creatorcontrib>Ota, Fumie</creatorcontrib><creatorcontrib>Tsukada, Yoshito</creatorcontrib><creatorcontrib>Motegi, Mitsuru</creatorcontrib><creatorcontrib>Nakasatomi, Masao</creatorcontrib><creatorcontrib>Sakairi, Toru</creatorcontrib><creatorcontrib>Ikeuchi, Hidekazu</creatorcontrib><creatorcontrib>Kaneko, Yoriaki</creatorcontrib><creatorcontrib>Hiromura, Keiju</creatorcontrib><creatorcontrib>Maeno, Toshitaka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamaguchi, Koichi</au><au>Yamaguchi, Aya</au><au>Ito, Masashi</au><au>Wakamatsu, Ikuo</au><au>Itai, Miki</au><au>Muto, Sohei</au><au>Uno, Shogo</au><au>Aikawa, Masaki</au><au>Kouno, Shunichi</au><au>Takemura, Masao</au><au>Yatomi, Masakiyo</au><au>Aoki-Saito, Haruka</au><au>Koga, Yasuhiko</au><au>Hara, Kenichiro</au><au>Motegi, Shinsuke</au><au>Tsukida, Mayuko</au><au>Ota, Fumie</au><au>Tsukada, Yoshito</au><au>Motegi, Mitsuru</au><au>Nakasatomi, Masao</au><au>Sakairi, Toru</au><au>Ikeuchi, Hidekazu</au><au>Kaneko, Yoriaki</au><au>Hiromura, Keiju</au><au>Maeno, Toshitaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical differences among patients with myeloperoxidase–antineutrophil cytoplasmic antibody–positive interstitial lung disease</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>42</volume><issue>2</issue><spage>479</spage><epage>488</epage><pages>479-488</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Introduction Patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis and idiopathic interstitial lung diseases (IIPs) are positive for myeloperoxidase (MPO)–ANCA. MPO–ANCA-positive vasculitis mainly comprises microscopic polyangiitis (MPA) and unclassifiable vasculitis. These diseases are frequently complicated by interstitial lung disease (ILD). Few studies have reported the clinical differences between the subtypes of MPO–ANCA-positive ILD. Therefore, this study aimed to examine the clinical findings and courses of MPO–ANCA-positive ILD. Method This retrospective study enrolled 100 patients with MPO–ANCA-positive ILD who were categorized into three groups: MPA ( n  = 44), unclassifiable vasculitis ( n  = 29), and IIP ( n  = 27). Our study compared the clinical findings and prognosis of these patients and analyzed the poor prognostic factors. Furthermore, we assessed the association between the patients with and without acute exacerbation of ILD (AE-ILD). Results Our study found clinical differences in serum markers, clinical symptoms, and treatment regimens among the three groups. ILD complications, as the main cause of death, differed among the three groups ( P  = 0.04). Patients with unclassifiable vasculitis showed higher survival rates than those with IIP ( P  = 0.046). Patients with AE-ILD showed fewer general symptoms ( P  = 0.02) and lower survival rates ( P  &lt; 0.01) than those without AE-ILD. In multivariate analysis, AE-ILD development was a strong poor prognostic factor for MPO–ANCA-positive ILD. Conclusions The subtypes of MPO–ANCA-positive ILD have different clinical features and prognoses. Patients who develop AE-ILD require careful evaluation of clinical courses. Key Points • In myeloperoxidase (MPO)–antineutrophil cytoplasmic antibody (ANCA)–positive interstitial lung disease (ILD), patients with unclassifiable vasculitis showed a better prognosis than those with idiopathic ILD. . • Development of acute exacerbation in ILD was a strong poor prognostic factor in patients with MPO–ANCA-positive ILD. .</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36194347</pmid><doi>10.1007/s10067-022-06388-5</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0085-7728</orcidid><orcidid>https://orcid.org/0000-0001-6840-515X</orcidid><orcidid>https://orcid.org/0000-0002-3982-7561</orcidid><orcidid>https://orcid.org/0000-0002-8612-8915</orcidid><orcidid>https://orcid.org/0000-0002-8428-2046</orcidid><orcidid>https://orcid.org/0000-0002-4974-9026</orcidid><orcidid>https://orcid.org/0000-0001-8019-7912</orcidid><orcidid>https://orcid.org/0000-0003-0701-6753</orcidid><orcidid>https://orcid.org/0000-0002-8753-7067</orcidid><orcidid>https://orcid.org/0000-0002-0768-7090</orcidid><orcidid>https://orcid.org/0000-0003-4567-6082</orcidid><orcidid>https://orcid.org/0000-0002-8428-1617</orcidid><orcidid>https://orcid.org/0000-0002-4303-330X</orcidid><orcidid>https://orcid.org/0000-0003-1198-8520</orcidid><orcidid>https://orcid.org/0000-0002-7047-7870</orcidid><orcidid>https://orcid.org/0000-0002-9490-8364</orcidid><orcidid>https://orcid.org/0000-0001-9329-1203</orcidid><orcidid>https://orcid.org/0000-0001-9030-2050</orcidid><orcidid>https://orcid.org/0000-0003-4212-7352</orcidid><orcidid>https://orcid.org/0000-0002-9498-6995</orcidid><orcidid>https://orcid.org/0000-0001-5755-0781</orcidid><orcidid>https://orcid.org/0000-0003-1154-1454</orcidid><orcidid>https://orcid.org/0000-0002-6251-7414</orcidid><orcidid>https://orcid.org/0000-0003-2804-485X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0770-3198
ispartof Clinical rheumatology, 2023-02, Vol.42 (2), p.479-488
issn 0770-3198
1434-9949
language eng
recordid cdi_proquest_miscellaneous_2721262828
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications
Antibodies
Antibodies, Antineutrophil Cytoplasmic
Antineutrophil cytoplasmic antibodies
Humans
Lung diseases
Lung Diseases, Interstitial
Medical prognosis
Medical treatment
Medicine
Medicine & Public Health
Microscopic Polyangiitis - complications
Multivariate analysis
Original Article
Patients
Peroxidase
Prognosis
Retrospective Studies
Rheumatology
Survival
Vasculitis
title Clinical differences among patients with myeloperoxidase–antineutrophil cytoplasmic antibody–positive interstitial lung disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T04%3A33%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20differences%20among%20patients%20with%20myeloperoxidase%E2%80%93antineutrophil%20cytoplasmic%20antibody%E2%80%93positive%20interstitial%20lung%20disease&rft.jtitle=Clinical%20rheumatology&rft.au=Yamaguchi,%20Koichi&rft.date=2023-02-01&rft.volume=42&rft.issue=2&rft.spage=479&rft.epage=488&rft.pages=479-488&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-022-06388-5&rft_dat=%3Cproquest_cross%3E2768915257%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2768915257&rft_id=info:pmid/36194347&rfr_iscdi=true